Immunovant (IMVT) Income towards Parent Company (2018 - 2026)

Immunovant (IMVT) has 9 years of Income towards Parent Company data on file, last reported at -$147.8 million in Q1 2026.

• Quarterly Income towards Parent Company fell 38.88% year-over-year to -$147.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$505.6 million (down 22.17% YoY) and the FY2026 annual result came in at -$505.6 million, down 22.17% from the prior year.
• Income towards Parent Company eased to -$147.8 million in Q1 2026, from -$110.6 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$40.4 million in Q2 2022 to a low of -$147.8 million in Q1 2026.
• A 5-year average of -$84.5 million and a median of -$75.3 million in 2024 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2023 — Income towards Parent Company climbed 18.68% — and 2024, when it plunged 116.11%.
• Tracing IMVT's Income towards Parent Company over 5 years: stood at -$63.2 million in 2022, then advanced by 18.68% to -$51.4 million in 2023, then sank by 116.11% to -$111.1 million in 2024, then advanced by 0.44% to -$110.6 million in 2025, then plunged by 33.63% to -$147.8 million in 2026.
• The last three Income towards Parent Company figures came in at -$147.8 million (Q1 2026), -$110.6 million (Q4 2025), and -$126.5 million (Q3 2025), per Business Quant data.